60302-87-6

Upstream product

• 40059-53-8 ethyl 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxylate 

Downstream Products

• 331963-46-3 C₁₇H₁₂ClN₃O₄ 
• 304878-16-8 C₁₇H₁₂ClN₃O₄ 
• 302785-62-2 C₁₇H₁₂N₄O₆ 
• 331963-49-6 C₁₇H₁₂BrN₃O₄ 
• 304878-45-3 C₁₇H₁₁Cl₂N₃O₄ 
• 304870-09-5 C₁₇H₁₂N₄O₆ 
• 331963-54-3 C₁₈H₁₅N₃O₄ 
• 1185758-25-1 C₁₇H₁₁N₅O₈ 
• 1263357-39-6 4-hydroxy-N'-[(1E)-(2-hydroxy-5-methoxyphenyl)methylene]-2-oxo-1,2-dihydroquinoline-3-carbohydrazide 
• 1263357-38-5 4-hydroxy-N'-[(1E)-(2-hydroxy-5-methylphenyl)methylene]-2-oxo-1,2-dihydroquinoline-3-carbohydrazide 
• 1263357-45-4 N'-[(1E)-(2,6-dichloro-3-nitrophenyl)methylene]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide 
• 1263357-37-4 N'-[(E)-(2,4-dihydroxyphenyl)methylidene]-4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carbohydrazide 

Relevant academic research and scientific papers

Synthesis, biological assessment and molecular modeling of new dihydroquinoline-3-carboxamides and dihydroquinoline-3-carbohydrazide derivatives as cholinesterase inhibitors, and Ca channel antagonists

The synthesis, biological evaluation, and molecular modeling of new 4-hydroxy-2-oxo-1,2-dihydroquinoline-3-carboxamides(4), 4-hydroxy-2-oxo-1,2- dihydroquinoline-3-carbohydrazide (6), and some hexahydropyrimido[5,4-c] quinoline-2,5-diones (9) produced earlier by our laboratory, as AChE/BuChE inhibitors, is described. From these analyses compound 4c resulted equipotent regarding the inhibition of cholinesterases'; inhibitors 6k, 9a, 9b were selective for AChE, whereas product 4d proved selective for BuChE. Docking analysis has been carry out in order to identify the binding mode in the active site, and to explain the observed selectivities. Only compound 9a has been shown to decrease K+-induced calcium signals in bovine chromaffin cells.